Key Highlights

  • Net loss for the third quarter ended September 30, 2026 was USD 27.3 million, or USD 0.58 per share, compared with USD 17.1 million, or USD 18.04 per share, in the third quarter of 2025.
  • Research and development expense rose to USD 24.6 million from USD 14.6 million a year earlier, while general and administrative expense reached USD 5.1 million against USD 2.5 million.
  • Cash, cash equivalents and marketable securities stood at USD 430.2 million at September 30, 2026, down from USD 457.5 million at June 30, and management said it funds operations into 2029.
  • The Phase 3 SOLARA trial of sutacimig in Glanzmann thrombasthenia was initiated in November 2026 and is expected to enroll about 75 participants aged 12 to 70.

Loss Widens as Spending Ramps Up After the IPO

Hemab Therapeutics (NASDAQ:COAG) filed its Quarterly Report on November 10, 2026, for the three months ended September 30, 2026. The clinical-stage company has no approved products and no product revenue, so the result is a net loss of USD 27.3 million. Loss from operations was USD 29.8 million, against USD 17.1 million a year earlier, and interest income of USD 3.4 million partly offset it. Operating expenses grew by USD 12.7 million, led by a USD 10.1 million rise in research and development. External costs for sutacimig reached USD 7.4 million from USD 4.5 million, tied to start-up work for the pivotal trial and Manufacturing costs. The company closed its initial public offering on May 4, 2026, raising about USD 317.2 million net.

What SOLARA and the Factor VII Data Add to the Picture

Hemab develops antibody therapies for blood coagulation disorders. Its lead asset, sutacimig, is a bispecific antibody now in Phase 3 for Glanzmann thrombasthenia. SOLARA is a single-arm study with a 24-week run-in, then 48 weeks of once-weekly subcutaneous dosing, so each participant acts as their own control. The FDA recommended that the company consider a randomized design, but acknowledged concerns about feasibility in a rare disease, and management said it chose a single-arm path. In Factor VII deficiency, two participants given a single dose showed prothrombin time shortened by more than 50%, with low-grade adverse events judged unrelated to treatment. These data come from only two people.

Cash Runway, Expense Pressure and the December Data Calendar

The cash balance fell by about USD 27.3 million between June 30 and September 30, 2026 (calculated from the two reported figures), close to the quarterly net loss. Management said that cash supports operations into 2029, but the filing warns that expenses will rise further as SOLARA enrolls and that substantial additional funding will be needed over time. On the call, management said updated Factor VII data will appear at the American Society of Hematology meeting on December 14, preclinical HMB-003 data on December 13, and new HMB-002 data in February 2027. Initial Phase 1 data for HMB-003 are expected in mid-2027.

Where Things Stand

The loss reflects deliberate spending rather than a setback. Hemab Therapeutics (NASDAQ:COAG) lost USD 27.3 million in the quarter as research costs climbed ahead of its first pivotal study, and its USD 430.2 million cash balance is described by management as sufficient into 2029. The main uncertainties are trial execution, the FDA's randomization comment and future funding needs. Next markers include first participants entering the SOLARA run-in in the fourth quarter of 2026, the December ASH presentations and HMB-002 results in February 2027.